Results 21 to 30 of about 1,580 (184)

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Journal of Clinical Medicine, 2023
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades
Scholtz, Smita (PD Dr. med.), Rudolph, Volker (PD Dr. med.), Reil, Jan-Christian (Dr. med.)   +2 more
core   +5 more sources

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy.
Anjali T. Owens, Milind Desai, Matthew T. Wheeler, Anna Rodonski, Samira Merali, Amy J. Sehnert, Sara Saberi   +6 more
doaj   +2 more sources

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system [PDF]

Open Heart
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients’ symptomatic ...
Tingting Wu, Jiahao Zhang, Jialing Qian, Qingqing Jiang   +3 more
doaj   +2 more sources

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions

Drug Design, Development and Therapy, 2023
Tiffany Dong,* Ben Alencherry,* Susan Ospina, Milind Y Desai Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA*These authors contributed equally to this workCorrespondence: Milind ...
Tiffany Dong, Ben Alencherry, Susan Ospina   +2 more
exaly   +2 more sources

Predictors of Higher Mavacamten Maintenance Dose in Obstructive Hypertrophic Cardiomyopathy [PDF]

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mavacamten has emerged as an effective therapy for obstructive hypertrophic cardiomyopathy (oHCM); however, interindividual variability in maintenance dosing remains a practical challenge in clinical practice.
Mustafa Suppah, MD, Humam Abo Abdullah, MD, Amro Badr, MD, Ramzi Ibrahim, MD, Juan Farina, MD, Chadi Ayoub, MBBS, PhD, Reza Arsanjani, MD, Jeffrey Geske, MD, Said Alsidawi, MD   +8 more
doaj   +2 more sources

Mavacamten in Right Ventricular Outflow Tract Obstruction

JACC: Case Reports
Right ventricular outflow tract (RVOT) obstruction is a rare complication of ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM). This study presents an unusual case of a patient with HCM with severe RVOT obstruction that was relieved successfully through the use of mavacamten.
Jasmine K. Malhi, Richard T. Carrick, Chloe Duvall, Faisal Rahman, Matthew W. Martinez, Jose Madrazo, Lili A. Barouch   +6 more
openaire   +4 more sources

Tale of three services: early UK experience with mavacamten treatment for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction [PDF]

Open Heart
Background Hypertrophic cardiomyopathy (HCM) is characterised by abnormal thickening of ventricular myocardium. Left ventricular outflow tract (LVOT) obstruction occurs in up to 70% of patients, causing progressive symptoms, heart failure and mortality ...
Jane Draper, Antonio De Marvao, Robert M Cooper, Gerry Carr-White, Nabeel Sheikh, Rachel Bastiaenen, Yande Kasolo, Jason N Dungu, Edward Burford   +8 more
doaj   +2 more sources

ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy

Open Heart
Background Mavacamten has revolutionised the treatment of hypertrophic obstructive cardiomyopathy (HOCM) but requires frequent follow-up. Routine ECG may offer an accessible tool to indicate response to therapy.
Tienush Rassaf, Florian Buehning, Tobias Lerchner, Julia Vogel, Lea Kolk, Lukas Vogel, Katharina Seuthe, Peter Ferdinandy, Amir Abbas Mahabadi, Lars Michel   +9 more
doaj   +2 more sources

Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction

Nature Communications
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin ...
Daniel Auguin, Julien Robert-Paganin, Stéphane Réty, Carlos Kikuti, Amandine David, Gabriele Theumer, Arndt W. Schmidt, Hans-Joachim Knölker, Anne Houdusse   +8 more
doaj   +2 more sources

Mavacamten maintenance dose determination

\(\bf Aims\) Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance
Scholtz, Smita (PD Dr. med.), Coppée, Cédric, Mohemed, Kawa (Dr. med.), Potratz, Max (Dr. med.), Sequeira, Vasco (Dr. rer. nat.), Rudolph, Volker (PD Dr. med.), Scholtz, Werner (Dr. med.), Reil, Jan-Christian (Dr. med.)   +7 more
openaire   +2 more sources